Accession Number:

AD1017950

Title:

Production of a Novel OX40 Ligand for Clinical Use

Descriptive Note:

Technical Report,30 Sep 2014,29 Sep 2015

Corporate Author:

Providence Portland Medical Center Portland United States

Personal Author(s):

Report Date:

2015-10-01

Pagination or Media Count:

9.0

Abstract:

Cancer cells have evolved to evade immune-mediated destruction through several documented mechanisms. Our group has developed a technique to enhance immune function in tumor-bearing hosts by targeting a protein on the surface of white blood cells, termed OX40. This type of immune modulation leads to therapeutic benefit in tumor-bearing mice. We have produced a protein that binds to the human OX40 protein and activates human white blood cells. We have a cell line that produces high quantities of this protein and our goal is to test this protein for safety and efficacy in non-human primates so that we can obtain FDA approval for clinical trials in cancer patients. The long-range goal of this proposal is translate these findings to prostate cancer patients.

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE